search
Back to results

Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea

Primary Purpose

Rosacea, Papulopustular

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Azelaic Acid foam 15%
Sponsored by
Clinical Research Center of the Carolinas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rosacea, Papulopustular focused on measuring Rosacea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female subjects age 18 or older.
  2. Diagnosis of moderate to severe papulopustular rosacea with IGA of 3- moderate or 4-severe.
  3. Presence of 12 - 50 inflammatory lesions and persistent erythema with or without telangiectasia.
  4. Subjects must read, understand, and sign the Informed Consent.
  5. Subjects must be willing and able to comply with study procedures and visit schedule requirements.
  6. Women of childbearing potential that are willing to use an acceptable method of contraception during the study.

Exclusion Criteria:

  1. Active or localized or systemic infections.
  2. Subjects must not be immunocompromised.
  3. Known unresponsiveness or allergy to azelaic acid.
  4. Subjects unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the clinical study, uncooperative attitude or unlikelihood of completing the study (e.g. drug or alcohol abuse).
  5. Subjects must not be pregnant or breastfeeding.
  6. Presence of dermatoses that might interfere with the ability to diagnose and/or evaluate rosacea.
  7. Presence of other types of rosacea.
  8. Laser surgery on the face for the treatment of telangiectasia or other conditions within 6 weeks of study enrollment.
  9. Use of medications or products for the treatment of rosacea or other medical conditions within the following time periods prior to study enrollment. Use of these medications will be prohibited during the trial.

    Topical Prescription or Nonprescription medications 6 weeks Oral retinoids 6 months Tetracycline (ex. doxycycline, minocycline 2 months Corticosteroids 4 weeks Erythromycin or azithromycin 4 weeks Other systemic medications to treat rosacea 6 weeks

  10. Refusal to sign the Informed Consent document or Photo Release document and/or refusal to comply with all follow-up requirements.
  11. Use of medications that are known to cause flushing.
  12. Dose changes in the last 90 days or initiation of beta-blockers, vasodilators, vasoconstrictors, nonsteroidal anti-inflammatory drugs, hormone therapy, and/or other drugs known to cause acneform eruptions.

    -

Sites / Locations

  • Clinical Research Center of the Carolinas

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Open Label Single Arm

Arm Description

Azelaic Acid Foam 15% applied twice daily

Outcomes

Primary Outcome Measures

Inflammatory Lesion Count
The change in inflammatory lesion counts at week 12 compared to baseline

Secondary Outcome Measures

Investigator Global Assessment
Severity of Disease by Investigator Global Assessment, Score of 0 (Clear) - 4(Severe)

Full Information

First Posted
December 12, 2017
Last Updated
July 23, 2019
Sponsor
Clinical Research Center of the Carolinas
Collaborators
Bayer
search

1. Study Identification

Unique Protocol Identification Number
NCT03418610
Brief Title
Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
Official Title
Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
December 6, 2017 (Actual)
Primary Completion Date
January 9, 2019 (Actual)
Study Completion Date
January 9, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinical Research Center of the Carolinas
Collaborators
Bayer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.
Detailed Description
This is a single site, single arm open label study of Azelaic Acid foam 15% for the treatment of moderate to severe papulopustular rosacea. All patients will apply Azelaic Acid foam twice daily. At scheduled visits, high resolution equipment will be used to measure 3D topographical values for elevation of papules and pustules to objectively evaluate reduction of papulopustular lesions. Investigator and subject assessments will also be completed to assess the level of rosacea at weeks 4,8 and 12.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rosacea, Papulopustular
Keywords
Rosacea

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
Single Site, Single Arm Open Label Study
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Open Label Single Arm
Arm Type
Other
Arm Description
Azelaic Acid Foam 15% applied twice daily
Intervention Type
Drug
Intervention Name(s)
Azelaic Acid foam 15%
Other Intervention Name(s)
Finacea
Intervention Description
mild to moderate rosacea
Primary Outcome Measure Information:
Title
Inflammatory Lesion Count
Description
The change in inflammatory lesion counts at week 12 compared to baseline
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Investigator Global Assessment
Description
Severity of Disease by Investigator Global Assessment, Score of 0 (Clear) - 4(Severe)
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female subjects age 18 or older. Diagnosis of moderate to severe papulopustular rosacea with IGA of 3- moderate or 4-severe. Presence of 12 - 50 inflammatory lesions and persistent erythema with or without telangiectasia. Subjects must read, understand, and sign the Informed Consent. Subjects must be willing and able to comply with study procedures and visit schedule requirements. Women of childbearing potential that are willing to use an acceptable method of contraception during the study. Exclusion Criteria: Active or localized or systemic infections. Subjects must not be immunocompromised. Known unresponsiveness or allergy to azelaic acid. Subjects unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the clinical study, uncooperative attitude or unlikelihood of completing the study (e.g. drug or alcohol abuse). Subjects must not be pregnant or breastfeeding. Presence of dermatoses that might interfere with the ability to diagnose and/or evaluate rosacea. Presence of other types of rosacea. Laser surgery on the face for the treatment of telangiectasia or other conditions within 6 weeks of study enrollment. Use of medications or products for the treatment of rosacea or other medical conditions within the following time periods prior to study enrollment. Use of these medications will be prohibited during the trial. Topical Prescription or Nonprescription medications 6 weeks Oral retinoids 6 months Tetracycline (ex. doxycycline, minocycline 2 months Corticosteroids 4 weeks Erythromycin or azithromycin 4 weeks Other systemic medications to treat rosacea 6 weeks Refusal to sign the Informed Consent document or Photo Release document and/or refusal to comply with all follow-up requirements. Use of medications that are known to cause flushing. Dose changes in the last 90 days or initiation of beta-blockers, vasodilators, vasoconstrictors, nonsteroidal anti-inflammatory drugs, hormone therapy, and/or other drugs known to cause acneform eruptions. -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Todd Schlesinger, MD, FAAD
Organizational Affiliation
Medical Director
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Research Center of the Carolinas
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea

We'll reach out to this number within 24 hrs